[Severe parkinsonism due to metoclopramide: the importance of early recognition]. / Ernstig parkinsonisme door metoclopramide: het belang van tijdige herkenning.
Ned Tijdschr Geneeskd
; 157(26): A6037, 2013.
Article
em Nl
| MEDLINE
| ID: mdl-23835236
ABSTRACT
In this article, we present 3 women aged 73, 85 and 88 years who developed metoclopramide-induced parkinsonism. Shortly after starting metoclopramide, bradykinesia and rigidity developed in all 3 patients; tremor and postural instability in 2 of them. We discontinued the metoclopramide after 3-6 months; 2 of the patients had fully recovered 4-6 months later. The 3rd patient died from pneumonia, however, 2 months after discontinuation. Metoclopramide, a dopamine D2-antagonist, is a frequently prescribed anti-emetic drug; however, evidence of its efficacy is limited. In many patients, domperidone, another dopamine D2-antagonist, seems to be a better alternative. Movement disorders due to domperidone are uncommon, presumably because it does not cross the blood-brain barrier. It is likely that metoclopramide-induced parkinsonism is not uncommon; however, it is under-recognized. Risk factors are female sex, advanced age, diabetes mellitus and polypharmacy. Follow-up on patients using metoclopramide is advised.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson Secundária
/
Metoclopramida
/
Antieméticos
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
Idioma:
Nl
Ano de publicação:
2013
Tipo de documento:
Article